Docetaxel or Cabazitaxel With or Without Darolutamide in mCRPC

PHASE2RecruitingINTERVENTIONAL

Enrollment

245

Participants

Timeline

Start Date

November 29, 2023

Primary Completion Date

May 31, 2027

Study Completion Date

May 31, 2028

Conditions

Metastatic Castration-resistant Prostate Cancer

Interventions

DRUG

Darolutamide

Darolutamide 600 mg b.i.d. until the end of the last taxane cycle

DRUG

Docetaxel or cabazitaxel

Docetaxel or cabazitaxel Q3W

Trial Locations (1)

RECRUITING

Erasmus MC Cancer Institute, Rotterdam